Biocon and Quark Pharmaceuticals gets DCGI’s approval for new drug ‘QPI-1007’

23 Jun 2016 Evaluate

Drug Controller General of India (DCGI) has given nod to Biocon and its partner Quark Pharmaceuticals to proceed with clinical trials on human subjects for a new drug candidate, 'QPI-1007' aimed for ocular neuroprotection. The company and Quark Pharmaceuticals have also randomized the first patient in India in the global Phase II/III study of the new drug candidate. Randomisation is the allocation of subjects to treatment groups to prevent selection and accidental bias.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

391.60 1.20 (0.31%)
31-Dec-2025 10:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1722.40
Dr. Reddys Lab 1267.05
Cipla 1498.15
Zydus Lifesciences 913.45
Lupin 2086.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×